SCHEMBL23382833

SCHEMBL23382833

CCC1(Oc2ccc(C(=O)OC3(C(F)(F)C(=O)O)CCCCC3)cc2)CCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CTSK P43235 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SLC6A9 P48067 1/20 0.32
▸ SLC6A2 P23975 2/20 0.31
▸ SLC6A4 P31645 2/20 0.31
▸ SLC6A3 Q01959 2/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ SLC6A5 Q9Y345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23382837 0.85 ADORA3 (0.35) ADORA3SMN1; SMN2NPSR1LMNATDP1
SCHEMBL23382836 0.85 ADORA3 (0.35) ADORA3SMN1; SMN2NPSR1LMNATDP1
SCHEMBL23382834 0.82 ADORA3 (0.48) ADORA3SMN1; SMN2CTSKCYP3A4CYP2C9
SCHEMBL23382835 0.81 ADORA3 (0.43) ADORA3SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL23383174 0.81 ADORA3 (0.40) ADORA3TDP1KMT2ASLC6A9SLC6A2
SCHEMBL23383171 0.81 KDM4E (0.37) ADORA3SMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL23382712 0.81 ADORA3 (0.39) ADORA3SMN1; SMN2NPSR1LMNATDP1
SCHEMBL23383172 0.79 CYP19A1 (0.37) ADORA3SMN1; SMN2NPSR1LMNAMEN1
SCHEMBL23382697 0.79 SMN1; SMN2 (0.39) ADORA3SMN1; SMN2NPSR1LMNATDP1
SCHEMBL23383170 0.78 CA12 (0.38) ADORA3TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process IDUA, SLC6A5, SLC6A9 ADORA3 2841/4885SMN1; SMN2 3745/4885NPSR1 3275/4885
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS IDUA, SLC6A5, SLC6A9 ADORA3 2841/4885SMN1; SMN2 3745/4885NPSR1 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback